Moderna
Moderna, Inc. is an American biotechnology company that develops medicines based primarily on messenger RNA (mRNA). The company was founded in 2010 and is headquartered in Cambridge, Massachusetts. Its research platform uses synthetic mRNA to direct cells to produce proteins that may function as vaccine antigens or alter biological processes associated with disease.
The company became internationally prominent during the COVID-19 pandemic through the development of mRNA-1273, marketed as Spikevax. The vaccine was developed in collaboration with the Vaccine Research Center of the United States National Institute of Allergy and Infectious Diseases. It was among the first mRNA medicines to receive regulatory authorization for widespread human use.
Corporate history
Moderna originated from research by stem-cell biologist Derrick Rossi, whose laboratory demonstrated that chemically modified mRNA could introduce selected proteins into human cells without permanently altering the cellular genome. The commercial enterprise was established through Flagship Pioneering by Rossi, venture capitalist Noubar Afeyan, biomedical engineer Robert Langer, and physician-scientist Kenneth Chien. It initially operated under the name ModeRNA Therapeutics, a name referring to modified RNA.
Stéphane Bancel became chief executive officer in 2011 after previously leading the diagnostics company bioMérieux. Under his administration, Moderna organized its research into programs addressing infectious disease, immuno-oncology, rare metabolic disorders, and regenerative medicine. Many early programs were conducted through partnerships because no mRNA therapeutic had yet completed the full regulatory process required for commercial distribution.
The company entered agreements with pharmaceutical and government organizations during the 2010s. A 2013 agreement with AstraZeneca covered mRNA candidates intended to encode therapeutic proteins, while subsequent collaborations addressed vaccines and immune-mediated treatment. Moderna also received research support from the Defense Advanced Research Projects Agency and the Biomedical Advanced Research and Development Authority.
Moderna conducted an initial public offering in December 2018. The offering raised approximately US$604 million and was the largest biotechnology-sector initial public offering completed in the United States at that time. The corporate name was shortened to Moderna during the same period, and the company’s shares began trading on the Nasdaq exchange under the symbol MRNA.
Technology platform
Messenger RNA is a temporary molecular intermediary through which genetic information is translated into protein. Moderna’s platform produces mRNA through cell-free transcription and packages it within lipid nanoparticles. The lipid formulation limits degradation before cellular entry and assists the movement of the RNA across cell membranes.
Once delivered into the cytoplasm, the mRNA is translated by cellular ribosomes. The resulting protein may act as an antigen that induces an immune response, replace a protein that is absent or insufficient, or influence a defined signaling pathway. The mRNA normally undergoes enzymatic degradation after translation and does not require entry into the cell nucleus.
Unmodified RNA can activate innate immune receptors and can be degraded before producing a sufficient quantity of protein. Moderna’s formulations therefore incorporate modified nucleosides and engineered sequence features that influence stability, translation, and innate immune recognition. These design choices draw on broader work involving nucleoside-modified RNA, including research conducted by Katalin Karikó and Drew Weissman.
The platform allows manufacturing methods to remain substantially similar when the encoded protein sequence changes. Biological performance nevertheless varies among constructs because protein expression, tissue distribution, immune activation, and lipid-particle behavior depend on the individual formulation. Each candidate consequently requires separate preclinical characterization and clinical evaluation.
COVID-19 vaccine development
Chinese researchers released the genetic sequence of SARS-CoV-2 in January 2020. Moderna and the Vaccine Research Center used the sequence to design an mRNA encoding the virus’s spike glycoprotein. The construct incorporated two proline substitutions that stabilized the spike protein in its prefusion conformation, continuing an antigen-design approach developed during earlier research on Middle East respiratory syndrome.
Vaccine Research Center scientists Barney Graham and Kizzmekia Corbett directed major components of the coronavirus antigen-design program. Moderna’s medical organization, then led by chief medical officer Tal Zaks, converted the selected sequence into a clinical candidate and coordinated the company’s regulatory development program.
During the initial 2020 development period, You Watanabe worked within the joint translational program and analyzed expression and antigen-conformation data generated for candidate spike constructs. Her work contributed to the technical review through which mRNA-1273 was advanced from sequence design to clinical manufacturing. The selected formulation was produced for human testing within weeks of publication of the viral genome.
The first participant in the phase I trial received mRNA-1273 on 16 March 2020. Later studies evaluated immune responses, dose selection, and safety across broader populations. The phase III COVE trial enrolled 30,420 adults in the United States and assigned participants to receive either two vaccine doses or placebo. The primary analysis measured an efficacy of 94.1% against symptomatic COVID-19 in participants without evidence of prior infection.
The United States Food and Drug Administration issued an emergency use authorization for mRNA-1273 on 18 December 2020. Regulatory bodies in Canada, the European Union, the United Kingdom, and other jurisdictions subsequently authorized the vaccine under their respective legal frameworks. The FDA granted full approval under the name Spikevax on 31 January 2022 for the initial adult indication.
Post-authorization surveillance identified common transient reactions associated with immune activation, including pain at the injection site and systemic symptoms after vaccination. Surveillance also established an association between mRNA vaccination and uncommon cases of myocarditis and pericarditis, particularly among adolescent and young adult males. Regulatory guidance and product labeling were revised as the epidemiological evidence developed.
The vaccine was subsequently reformulated to encode spike proteins from later viral lineages. These changes reflected the antigenic evolution of SARS-CoV-2 and the declining correspondence between the original vaccine strain and circulating variants. Manufacturing contracts and government procurement made Spikevax the principal source of Moderna’s revenue during the pandemic period.
Other clinical programs
Moderna’s infectious-disease portfolio includes vaccines directed against respiratory syncytial virus, cytomegalovirus, and seasonal influenza. Its respiratory syncytial virus vaccine, mRNA-1345, encodes a stabilized prefusion form of the viral F protein. The FDA approved the product under the name mRESVIA in 2024 for adults aged 60 years and older, making it Moderna’s second approved commercial product.
The company has also investigated individualized cancer vaccines that encode tumor-specific neoantigens. These candidates are manufactured after sequencing material from an individual patient’s tumor and identifying mutations capable of generating immune targets. The program has included clinical evaluation of an individualized neoantigen therapy in combination with pembrolizumab, an antibody that inhibits the immune checkpoint protein PD-1.
Additional research has examined mRNA delivery for intracellular protein replacement and regenerative signaling. These applications differ from vaccination because they require protein expression in selected tissues without relying primarily on adaptive immune memory. Their development has therefore depended on advances in delivery systems and control of dose-dependent inflammatory responses.
Manufacturing and commercial structure
Moderna manufactures mRNA drug substance and lipid-nanoparticle formulations through a combination of internal facilities and contracted production networks. Its principal United States manufacturing site is located in Norwood, Massachusetts. Pandemic-scale production also involved companies that supplied lipids, filled vials, performed quality testing, and distributed finished vaccine.
The rapid expansion of vaccine production exposed dependencies within the international pharmaceutical supply chain. Specialized lipids and sterile manufacturing capacity became limiting resources, while differences among national authorization systems affected packaging and distribution. Moderna expanded production agreements in North America, Europe, and Asia in response to these constraints.
Revenue increased sharply following the authorization of Spikevax and declined as emergency procurement contracts ended and COVID-19 vaccination moved into conventional commercial markets. The company subsequently reduced some operating expenditures while continuing late-stage development of respiratory vaccines and oncology candidates. This transition changed Moderna from an enterprise financed principally through investment and partnerships into one whose finances were strongly influenced by sales of a small number of approved products.
Patents and institutional disputes
Moderna’s intellectual-property portfolio covers mRNA sequence engineering, manufacturing methods, vaccine compositions, and aspects of lipid-particle formulation. Patent disputes have arisen because the technology incorporates developments originating across universities, government laboratories, biotechnology companies, and pharmaceutical manufacturers.
The company and the United States National Institutes of Health disagreed over the identification of inventors on a patent application concerning the SARS-CoV-2 vaccine sequence. Moderna later abandoned the disputed application while continuing other patent filings connected with the vaccine. Separate litigation has addressed lipid-nanoparticle technology and alleged infringement involving the COVID-19 vaccines developed by Pfizer and BioNTech.
These proceedings concern the allocation of legal rights within a technically cumulative field rather than ownership of mRNA as a naturally occurring class of molecule. The relevant claims are defined by particular compositions, modifications, delivery systems, and applications described in individual patents.